Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7553) 7553
Publication (788) 788
Book Review (102) 102
Book / eBook (97) 97
Book Chapter (41) 41
Conference Proceeding (11) 11
Dissertation (6) 6
Data Set (4) 4
Magazine Article (2) 2
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (5472) 5472
index medicus (4156) 4156
humans (3990) 3990
animals (3703) 3703
stroke (3273) 3273
female (2797) 2797
rats (2586) 2586
middle aged (2495) 2495
neurosciences (2173) 2173
aged (2087) 2087
clinical neurology (1748) 1748
infarction, middle cerebral artery - drug therapy (1710) 1710
ischemia (1634) 1634
disease models, animal (1599) 1599
rats, sprague-dawley (1451) 1451
brain ischemia - drug therapy (1340) 1340
treatment outcome (1328) 1328
brain (1169) 1169
risk factors (1145) 1145
peripheral vascular disease (1144) 1144
infarction, middle cerebral artery - pathology (1091) 1091
adult (1051) 1051
time factors (1026) 1026
neuroprotection (1025) 1025
infarction (1007) 1007
stroke - drug therapy (975) 975
cerebral infarction (973) 973
mice (967) 967
neurology (943) 943
neuroprotective agents - pharmacology (900) 900
cerebral ischemia (851) 851
brain ischemia - pathology (804) 804
brain - pathology (803) 803
neuroprotective agents - therapeutic use (795) 795
aged, 80 and over (774) 774
research (698) 698
reperfusion (697) 697
artery occlusion (691) 691
brain - drug effects (686) 686
infarction, middle cerebral artery - complications (683) 683
magnetic resonance imaging (676) 676
rats, wistar (662) 662
myocardial-infarction (648) 648
mortality (634) 634
cerebral infarction - drug therapy (625) 625
medicine (614) 614
pharmacology & pharmacy (614) 614
cardiovascular diseases (612) 612
myocardial infarction (597) 597
thrombolysis (590) 590
infarction, middle cerebral artery - physiopathology (587) 587
health aspects (581) 581
inflammation (574) 574
care and treatment (563) 563
therapy (561) 561
infarction, middle cerebral artery - metabolism (550) 550
research article (550) 550
surgery (548) 548
thrombolytic therapy (548) 548
apoptosis (547) 547
acute ischemic-stroke (542) 542
dose-response relationship, drug (524) 524
focal cerebral-ischemia (507) 507
analysis (499) 499
ischemic stroke (494) 494
stroke - pathology (492) 492
oxidative stress (483) 483
rodents (483) 483
brain - metabolism (480) 480
injury (476) 476
cerebral infarction - pathology (475) 475
expression (475) 475
cardiovascular disease (474) 474
cerebral blood flow (470) 470
retrospective studies (469) 469
brain ischemia - physiopathology (468) 468
brain ischemia - metabolism (461) 461
cerebral-artery occlusion (453) 453
occlusion (453) 453
prospective studies (444) 444
rat (442) 442
tomography, x-ray computed (442) 442
cardiac & cardiovascular systems (440) 440
tissue plasminogen activator - therapeutic use (440) 440
mice, inbred c57bl (434) 434
article (430) 430
fibrinolytic agents - therapeutic use (428) 428
prognosis (424) 424
hematology (423) 423
multidisciplinary sciences (421) 421
neurons - drug effects (417) 417
patients (412) 412
neurons (409) 409
middle cerebral artery occlusion (405) 405
stroke - etiology (404) 404
brain ischemia - complications (399) 399
risk (395) 395
heart attacks (393) 393
drug therapy (392) 392
acute myocardial-infarction (391) 391
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (84) 84
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Scarborough Hospital - General (2) 2
UTL at Downsview - May be requested (2) 2
Baycrest Hospital - Wellness Library (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
OISE - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Missing (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Victoria University Emmanuel College - Stacks (1) 1
West Park Healthcare Centre - Missing (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7475) 7475
Chinese (63) 63
Japanese (46) 46
German (34) 34
Spanish (30) 30
Russian (14) 14
French (12) 12
Norwegian (4) 4
Italian (3) 3
Hungarian (1) 1
Icelandic (1) 1
Korean (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan
by Ogawa, Akira and Mori, Etsuro and Minematsu, Kazuo and Taki, Waro and Takahashi, Akira and Nemoto, Shigeru and Miyamoto, Susumu and Sasaki, Makoto and Inoue, Takashi and MELT Japan Study Grp and MELT Japan Study Group
Stroke, ISSN 0039-2499, 10/2007, Volume 38, Issue 10, pp. 2633 - 2639
Background and Purpose - The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan was organized to determine the safety and... 
Urokinase | Stroke | Local fibrinolysis | Acute | Middle cerebral artery | INTRAVENOUS THROMBOLYSIS | acute | urokinase | ECASS | stroke | middle cerebral artery | CLINICAL NEUROLOGY | PROUROKINASE | INFARCTION | THERAPY | TISSUE-PLASMINOGEN-ACTIVATOR | local fibrinolysis | ACUTE ISCHEMIC-STROKE | PERIPHERAL VASCULAR DISEASE | COMPLICATIONS | TERRITORY STROKE | OCCLUSION | Cerebral Hemorrhage - chemically induced | Infarction, Middle Cerebral Artery - prevention & control | Acute Disease | Urokinase-Type Plasminogen Activator - adverse effects | Humans | Japan | Middle Aged | Male | Survival Rate | Treatment Outcome | Brain Ischemia - prevention & control | Time Factors | Brain Ischemia - drug therapy | Thrombolytic Therapy | Female | Aged | Infarction, Middle Cerebral Artery - drug therapy | Urokinase-Type Plasminogen Activator - administration & dosage | Infusions, Intra-Arterial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial
by Khatri, Pooja, Prof and Yeatts, Sharon D, PhD and Mazighi, Mikael, MD and Broderick, Joseph P, Prof and Liebeskind, David S, Prof and Demchuk, Andrew M, Prof and Amarenco, Pierre, Prof and Carrozzella, Janice, MSN and Spilker, Judith, BSN and Foster, Lydia D, PhD and Goyal, Mayank, Prof and Hill, Michael D, Prof and Palesch, Yuko Y, Prof and Jauch, Edward C, Prof and Haley, E Clarke, Prof and Vagal, Achala, MD and Tomsick, Thomas A, Prof and IMS III Trialists
Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 6, pp. 567 - 574
Summary Background The IMS III trial did not show a clinical benefit of endovascular treatment compared with intravenous alteplase (recombinant tissue... 
Neurology | ENDOVASCULAR THERAPY | REVASCULARIZATION | METHODOLOGY | TISSUE-PLASMINOGEN ACTIVATOR | RECANALIZATION | GUIDELINES | DEVICE | POOLED ANALYSIS | MERCI | CLINICAL NEUROLOGY | Carotid Artery Diseases - surgery | Stroke - diagnostic imaging | Humans | Middle Aged | Male | Cerebral Angiography - methods | Young Adult | Stroke - surgery | Carotid Artery Diseases - diagnostic imaging | Time Factors | Adult | Female | Infarction, Middle Cerebral Artery - drug therapy | Infarction, Middle Cerebral Artery - diagnostic imaging | Carotid Artery Diseases - drug therapy | Tomography Scanners, X-Ray Computed | Endovascular Procedures - adverse effects | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Stroke - drug therapy | Reperfusion - adverse effects | Endovascular Procedures - methods | Brain Ischemia - drug therapy | Adolescent | Infarction, Middle Cerebral Artery - surgery | Aged | Fibrinolytic Agents - administration & dosage | Reperfusion - methods | Brain Ischemia - diagnostic imaging | Brain Ischemia - surgery | Stroke (Disease) | Clinical trials | Ischemia | Tissue plasminogen activator | Patient outcomes | Studies | Aneurysms | Medical imaging | Clinical outcomes | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cerebralcare Granule® attenuates blood–brain barrier disruption after middle cerebral artery occlusion in rats
by Huang, Ping and Zhou, Chang-Man and Qin-Hu and Liu, Yu-Ying and Hu, Bai-He and Chang, Xin and Zhao, Xin-Rong and Xu, Xiang-Shun and Li, Quan and Wei, Xiao-Hong and Mao, Xiao-Wei and Wang, Chuan-She and Fan, Jing-Yu and Han, Jing-Yan
Experimental Neurology, ISSN 0014-4886, 10/2012, Volume 237, Issue 2, pp. 453 - 463
Disruption of blood–brain barrier (BBB) and subsequent edema are major contributors to the pathogenesis of ischemic stroke, for which the current clinical... 
Caveolin-1 | Chinese medicine | Ischemic stroke | Tight junction proteins | Blood–brain barrier | Blood-brain barrier | INJURY | REPERFUSION | FOCAL ISCHEMIA | TIGHT JUNCTION | NEUROSCIENCES | DECOMPRESSIVE CRANIECTOMY | ACUTE ISCHEMIC-STROKE | IN-VIVO | THROMBOLYSIS | MICE | INTRACRANIAL-PRESSURE | Microscopy, Electron, Transmission | Brain Edema - etiology | Cerebrovascular Circulation - drug effects | Capillary Permeability - drug effects | Rats | Male | Infarction, Middle Cerebral Artery - pathology | Blood-Brain Barrier - drug effects | Rats, Sprague-Dawley | Blotting, Western | Brain Edema - prevention & control | Blood-Brain Barrier - pathology | Magnetic Resonance Imaging | Microscopy, Confocal | Animals | Infarction, Middle Cerebral Artery - complications | Infarction, Middle Cerebral Artery - drug therapy | Drugs, Chinese Herbal - therapeutic use | Proteins | Permeability | Indexing in process
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Piperine suppresses cerebral ischemia–reperfusion-induced inflammation through the repression of COX-2, NOS-2, and NF-κB in middle cerebral artery occlusion rat model
by Vaibhav, Kumar and Shrivastava, Pallavi and Javed, Hayate and Khan, Andleeb and Ahmed, Md Ejaz and Tabassum, Rizwana and Khan, Mohd Moshahid and Khuwaja, Gulrana and Islam, Farah and Saeed Siddiqui, M and Safhi, Mohammed M and Islam, Fakhrul
Molecular and Cellular Biochemistry, ISSN 0300-8177, 8/2012, Volume 367, Issue 1, pp. 73 - 84
The pathophysiological mechanisms leading to neuronal injury in middle cerebral artery occlusion (MCAO) model of cerebral stroke are complex and multifactorial... 
Life Sciences | Biochemistry, general | MCAO | NF-κB | Piperine | COX-2 | NOS-2 | Medical Biochemistry | Oncology | Behavioral deficit | Cardiology | ACTIVATION | CYCLOOXYGENASE-2 | NITRIC-OXIDE SYNTHASE-2 | STROKE PATIENTS | CYTOKINE EXPRESSION | DAMAGE | CELL BIOLOGY | INFARCT VOLUME | NF-kappa B | MICE | STRESS | PROSTAGLANDIN E-2 | Reperfusion Injury - etiology | Rats, Wistar | Motor Activity - drug effects | Male | NF-kappa B - metabolism | Neuroprotective Agents - pharmacology | Piperidines - pharmacology | Cyclooxygenase 2 - genetics | Infarction, Middle Cerebral Artery - complications | Infarction, Middle Cerebral Artery - drug therapy | Cytokines - blood | Alkaloids - pharmacology | Reperfusion Injury - pathology | Anti-Inflammatory Agents - pharmacology | Cytokines - secretion | Inflammation Mediators - blood | Rats | Infarction, Middle Cerebral Artery - pathology | Down-Regulation - drug effects | Animals | Reperfusion Injury - prevention & control | NF-kappa B - genetics | Nitric Oxide Synthase Type II - genetics | Cyclooxygenase 2 - metabolism | Polyunsaturated Alkamides - pharmacology | Muscle Strength - drug effects | Benzodioxoles - pharmacology | Nitric Oxide Synthase Type II - metabolism | Index Medicus | Brain | Stroke | Antiinflammatory agents | Neurons | Inflammation | Interleukin 6 | NF- Kappa B protein | Reperfusion | Ischemia | Cell death | Cerebral blood flow | Interleukin 1 | Cyclooxygenase-2 | Injuries | Tumor necrosis factor- alpha
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Neuroprotective effect of nobiletin on cerebral ischemia–reperfusion injury in transient middle cerebral artery-occluded rats
by Yasuda, Nodoka and Ishii, Takayuki and Oyama, Dai and Fukuta, Tatsuya and Agato, Yurika and Sato, Akihiko and Shimizu, Kosuke and Asai, Tomohiro and Asakawa, Tomohiro and Kan, Toshiyuki and Yamada, Shizuo and Ohizumi, Yasushi and Oku, Naoto
Brain Research, ISSN 0006-8993, 2014, Volume 1559, pp. 46 - 54
Abstract Nobiletin, a citrus polymethoxylated flavone, is reported to possess various pharmacological activities such as anticancer, anti-inflammation, and... 
Neurology | Citrus polymethoxylated flavone | Ischemic stroke | Neutrophil infiltration | Nobiletin | Neuroprotectant | Motor function deficit | TARGET | IMPROVES MEMORY IMPAIRMENT | FOCAL ISCHEMIA | NEUROSCIENCES | STROKE | INFLAMMATION | MICE | EXPRESSION | BRAIN | Neurons - pathology | Rats, Wistar | Apoptosis - drug effects | Reperfusion Injury - drug therapy | Motor Activity - drug effects | Male | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Ischemic Attack, Transient - complications | Neuroprotective Agents - pharmacology | Neuroprotective Agents - pharmacokinetics | Infarction, Middle Cerebral Artery - complications | Infarction, Middle Cerebral Artery - drug therapy | Reperfusion Injury - complications | Neurons - drug effects | Flavones - pharmacology | Disease Models, Animal | Ischemic Attack, Transient - pathology | Neutrophils - pathology | Ischemic Attack, Transient - drug therapy | Brain Edema - etiology | Flavones - pharmacokinetics | Reperfusion Injury - pathology | Brain Edema - pathology | Neutrophils - drug effects | Rats | Treatment Outcome | Infarction, Middle Cerebral Artery - pathology | Brain - drug effects | Animals | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Brain - pathology | Brain Edema - drug therapy | Antioxidants | Brain | Brain damage | Cerebral ischemia | Alzheimer's disease | Protein binding | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats
by Gong, Gu and Xiang, Lei and Yuan, Libang and Hu, Ling and Wu, Wei and Cai, Lin and Yin, Liang and Dong, Hailong
PLoS ONE, ISSN 1932-6203, 03/2014, Volume 9, Issue 3, p. e89450
Aim: Glycyrrhizin (GL) has been reported to protect against ischemia and reperfusion (I/R)-induced injury by inhibiting the cytokine activity of high mobility... 
ISCHEMIA-REPERFUSION INJURY | STROKE | CELLS | LIVER-INJURY | CHROMATIN PROTEIN HMGB1 | POSTISCHEMIC BRAIN | MEDIATOR | MULTIDISCIPLINARY SCIENCES | IN-VIVO | MOBILITY GROUP BOX-1 | HMG-1 | Neuroprotective Agents - therapeutic use | Cerebral Infarction - drug therapy | Inflammation - pathology | Apoptosis - drug effects | Reperfusion Injury - drug therapy | JNK Mitogen-Activated Protein Kinases - metabolism | Male | Cerebral Infarction - complications | Reperfusion Injury - blood | Inflammation - complications | Brain Ischemia - blood | Glycyrrhizic Acid - pharmacology | Neuroprotective Agents - pharmacology | Infarction, Middle Cerebral Artery - complications | Inflammation - drug therapy | Cerebral Infarction - blood | HMGB1 Protein - metabolism | Infarction, Middle Cerebral Artery - drug therapy | Reperfusion Injury - complications | p38 Mitogen-Activated Protein Kinases - metabolism | HMGB1 Protein - antagonists & inhibitors | Cerebral Infarction - pathology | Brain Ischemia - complications | Reperfusion Injury - pathology | Antioxidants - pharmacology | Infarction, Middle Cerebral Artery - pathology | Rats, Sprague-Dawley | Infarction, Middle Cerebral Artery - blood | Glycyrrhizic Acid - therapeutic use | Animals | MAP Kinase Signaling System - drug effects | Brain Ischemia - drug therapy | Brain Ischemia - pathology | Oxidative Stress - drug effects | Oxidative stress | Brain | Chromosomal proteins | Cytokines | Ischemia | Inflammation | Enzyme-linked immunosorbent assay | Apoptosis | Occlusion | Cytochrome | Cerebral cortex | Kinases | Caspase-3 | HMGB1 protein | Western blotting | Interleukin 6 | Reperfusion | Cerebral blood flow | Rodents | Inhibition | Pretreatment | Glycyrrhizin | Cortex | Rats | Caspase | JNK protein | Tumor necrosis factor-α | Nitric-oxide synthase | Neurological diseases | Polymerase chain reaction | Cytochrome c | Serum levels | Signaling | Injury prevention | Molecular modelling | Nitric oxide | Immunofluorescence
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion
by Liu, Yanqun and Liu, Yanqun and Tang, Guanghui and Li, Yaning and Li, Yaning and Wang, Yang and Wang, Yang and Chen, Xiaoyan and Chen, Xiaoyan and Gu, Xiang and Gu, Xiang and Zhang, Zhijun and Zhang, Zhijun and Wang, Yongting and Yang, Guo-Yuan
Journal of neuroinflammation, ISSN 1742-2094, 2014, Volume 11, Issue 1, pp. 177 - 177
Background: Metformin, a widely used hypoglycemic drug, reduces stroke incidence and alleviates chronic inflammation in clinical trials. However, the effect of... 
DRUG | ACTIVATED PROTEIN-KINASE | INJURY | ISCHEMIA | ICAM-1 | Inflammation | FACTOR-KAPPA-B | Ischemic stroke | IMMUNOLOGY | NEUROSCIENCES | Blood-brain barrier | PATHWAY | AMPK | NEUROGENESIS | Metformin | INDEXES | Hypoglycemic Agents - therapeutic use | AMP-Activated Protein Kinases - metabolism | Hypoxia - drug therapy | Metformin - therapeutic use | Cytokines - metabolism | Cells, Cultured | Male | Infarction, Middle Cerebral Artery - pathology | Blood-Brain Barrier - drug effects | Blood-Brain Barrier - metabolism | Gene Expression Regulation - drug effects | Glucose - deficiency | Intercellular Adhesion Molecule-1 - metabolism | Animals | Signal Transduction - drug effects | Time Factors | Platelet Endothelial Cell Adhesion Molecule-1 - metabolism | Infarction, Middle Cerebral Artery - drug therapy | Mice | Zonula Occludens-1 Protein - metabolism | Brain Infarction - drug therapy | Neutrophil Infiltration - drug effects | Disease Models, Animal | Type 2 diabetes | Brain | Computer software industry | Health aspects | Injuries | Enzymes | Stroke | Data analysis | Heart attacks | Permeability | Cell adhesion & migration | Studies | Brain research | Ischemia | Rodents | Surgery | Brain damage | Diabetes | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Refining angiographic biomarkers of revascularization: Improving outcome prediction after intra-arterial therapy
by Yoo, Albert J and Simonsen, Claus Z and Prabhakaran, Shyam and Chaudhry, Zeshan A and Issa, Mohammad A and Fugate, Jennifer E and Linfante, Italo and Liebeskind, David S and Khatri, Pooja and Jovin, Tudor G and Kallmes, David F and Dabus, Guilherme and Zaidat, Osama O and Cerebral Angiographic and Cerebral Angiographic Revascularization Grading Collaborators
Stroke, ISSN 0039-2499, 09/2013, Volume 44, Issue 9, pp. 2509 - 2512
Background and Purpose Angiographic revascularization grading after intra-arterial stroke therapy is limited by poor standardization, making it unclear which... 
Modified TICI | Intra-arterial therapy | Acute ischemic stroke | Endovascular | TIMI | Revascularization | revascularization | RECANALIZATION | THROMBECTOMY | REPERFUSION | CLINICAL NEUROLOGY | TRIAL | endovascular | acute ischemic stroke | ACUTE ISCHEMIC-STROKE | THROMBOLYSIS | PERIPHERAL VASCULAR DISEASE | intra-arterial therapy | modified TICI | Infarction, Middle Cerebral Artery - physiopathology | Predictive Value of Tests | Prognosis | Cerebrovascular Circulation - drug effects | Humans | Middle Aged | Injections, Intra-Arterial - standards | Male | Treatment Outcome | Trauma Severity Indices | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Biomarkers | Female | Aged | Fibrinolytic Agents - administration & dosage | Infarction, Middle Cerebral Artery - drug therapy | Retrospective Studies | Thrombolytic Therapy - standards | Cerebral Angiography - standards | Infarction, Middle Cerebral Artery - diagnostic imaging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plasminogen activator in acute middle cerebral artery main stem occlusion: Results from a randomized study
by Eggers, Jürgen and König, Inke R and Koch, Björn and Händler, Götz and Seidel, Günter
Stroke, ISSN 0039-2499, 05/2008, Volume 39, Issue 5, pp. 1470 - 1475
Background and Purpose-Sonothrombolysis is a new treatment approach in acute ischemic stroke. The results of a monocenter, randomized clinical study are... 
Transcranial ultrasound | Stroke | Ischemic | Acute | Thrombolytic therapy | acute | CLINICAL-TRIAL | THROMBOSIS | LOW-FREQUENCY | RECANALIZATION | SKULL | MODEL | stroke | transcranial ultrasound | CLINICAL NEUROLOGY | ischemic | BRAIN ISCHEMIA | ULTRASOUND | ACUTE ISCHEMIC-STROKE | thrombolytic therapy | THROMBOLYSIS | PERIPHERAL VASCULAR DISEASE | Intracranial Hemorrhages - physiopathology | Recombinant Proteins - therapeutic use | Infarction, Middle Cerebral Artery - physiopathology | Humans | Middle Aged | Intracranial Hemorrhages - etiology | Middle Cerebral Artery - drug effects | Male | Treatment Outcome | Brain Ischemia - physiopathology | Tissue Plasminogen Activator - therapeutic use | Acute Disease - therapy | Ultrasonography, Doppler, Transcranial - methods | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Middle Cerebral Artery - physiopathology | Female | Aged | Infarction, Middle Cerebral Artery - drug therapy | Infarction, Middle Cerebral Artery - diagnostic imaging | Brain Ischemia - diagnostic imaging | Middle Cerebral Artery - diagnostic imaging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Good clinical outcome after ischemic stroke with successful revascularization is time-dependent
by Khatri, P and Abruzzo, T and Yeatts, S.D and Nichols, C and Broderick, J.P and Tomsick, T.A and IMS I & II Investigators and IMS I and II Investigators and For the IMS I and II Investigators
Neurology, ISSN 0028-3878, 2009, Volume 73, Issue 13, pp. 1066 - 1072
Background: Trials of IV recombinant tissue plasminogen activator (rt-PA) have demonstrated that longer times from ischemic stroke symptom onset to initiation... 
MIDDLE CEREBRAL-ARTERY | MERCI TRIAL | INTERVENTIONAL MANAGEMENT | TISSUE-PLASMINOGEN-ACTIVATOR | RT-PA STROKE | ALTEPLASE | RECANALIZATION | PROACT-II | THROMBOLYSIS | EARLY REPERFUSION | CLINICAL NEUROLOGY | Severity of Illness Index | Injections, Intravenous | Humans | Middle Aged | Carotid Stenosis - drug therapy | Male | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Young Adult | Pilot Projects | Cerebral Angiography | Time Factors | Brain Ischemia - drug therapy | Aged, 80 and over | Adult | Cerebral Revascularization - methods | Female | Aged | Fibrinolytic Agents - administration & dosage | Infarction, Middle Cerebral Artery - drug therapy | Carotid Stenosis - diagnostic imaging | Infarction, Middle Cerebral Artery - diagnostic imaging | Brain Ischemia - diagnostic imaging | Injections, Intra-Arterial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Effects of 0.6 mg/kg Intravenous Alteplase on Vascular and Clinical Outcomes in Middle Cerebral Artery Occlusion: Japan Alteplase Clinical Trial II (J-ACT II)
by Mori, Etsuro and Minematsu, Kazuo and Nakagawara, Jyoji and Yamaguchi, Takenori and Sasaki, Makoto and Hirano, Teruyuki and J ACT II Grp and Japan Alteplase Clinical Trial II Group
Stroke, ISSN 0039-2499, 03/2010, Volume 41, Issue 3, pp. 461 - 465
Background and Purpose-The purpose of this study was to evaluate further the efficacy of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in... 
Recanalization | Acute ischemic stroke | Tissue plasminogen activator | Middle cerebral artery occlusion | Magnetic resonance angiography | tissue plasminogen activator | CAROTID-ARTERY | RANDOMIZED-TRIAL | recanalization | MRI PARAMETERS | CLINICAL NEUROLOGY | PROUROKINASE | TISSUE-PLASMINOGEN-ACTIVATOR | acute ischemic stroke | PREDICTORS | ACUTE ISCHEMIC-STROKE | EMBOLIC STROKE | THROMBOLYSIS | PERIPHERAL VASCULAR DISEASE | magnetic resonance angiography | middle cerebral artery occlusion | Injections, Intravenous | Prospective Studies | Humans | Japan | Middle Aged | Middle Cerebral Artery - drug effects | Male | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Radiography | Time Factors | Aged, 80 and over | Female | Magnetic Resonance Angiography - methods | Aged | Infarction, Middle Cerebral Artery - drug therapy | Infarction, Middle Cerebral Artery - diagnostic imaging | Cohort Studies | Middle Cerebral Artery - diagnostic imaging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke
by Simao, Fabricio and Ustunkaya, Tuna and Clermont, Allen C and Feener, Edward P
Blood, ISSN 0006-4971, 04/2017, Volume 129, Issue 16, pp. 2280 - 2290
Thrombolytic therapy using tissue plasminogen activator (tPA) in acute stroke is associated with increased risks of cerebral hemorrhagic transformation and... 
MATRIX METALLOPROTEINASES | CONTACT SYSTEM | BARRIER PERMEABILITY | THROMBUS FORMATION | OROLINGUAL ANGIOEDEMA | INTRACEREBRAL HEMORRHAGE | HEMATOLOGY | FACTOR-XII | ISCHEMIC-STROKE | THROMBOLYTIC THERAPY | MOLECULAR-MECHANISMS | Plasma Kallikrein - metabolism | Humans | Male | Cerebral Hemorrhage - genetics | Stroke - genetics | Tissue Plasminogen Activator - adverse effects | Cerebral Hemorrhage - blood | Stroke - pathology | Fibrinolytic Agents - adverse effects | Plasma Kallikrein - genetics | Matrix Metalloproteinase 9 - metabolism | Matrix Metalloproteinase 9 - genetics | Infarction, Middle Cerebral Artery - genetics | Infarction, Middle Cerebral Artery - drug therapy | Thrombosis - blood | Disease Models, Animal | Cerebral Hemorrhage - chemically induced | Gene Expression | Factor XII - genetics | Stroke - drug therapy | Infarction, Middle Cerebral Artery - pathology | Angioedema - genetics | Infarction, Middle Cerebral Artery - blood | Mice, Knockout | Stroke - blood | Thrombosis - pathology | Administration, Intravenous | Animals | Angioedema - blood | Factor XII - metabolism | Thrombolytic Therapy | Angioedema - chemically induced | Thrombosis - genetics | Mice | Thrombosis - drug therapy | Index Medicus | Abridged Index Medicus | Thrombosis and Hemostasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign
by Mattle, Heinrich P and Arnold, Marcel and Georgiadis, Dimitrios and Baumann, Christian and Nedeltchev, Krassen and Benninger, David and Remonda, Luca and Von Büdingen, Christian and Diana, Anca and Pangalu, Athina and Schroth, Gerhard and Baumgartner, Ralf W
Stroke, ISSN 0039-2499, 2008, Volume 39, Issue 2, pp. 379 - 383
Background and Purpose - It is unclear whether intraarterial (IAT) or intravenous (IVT) thrombolysis is more effective for ischemic stroke with hyperdense... 
Therapy | Thrombolysis | Acute stroke | TISSUE-PLASMINOGEN ACTIVATOR | therapy | RECANALIZATION | CLINICAL NEUROLOGY | TRIAL | INFARCTION | acute stroke | thrombolysis | PROACT-II | PERIPHERAL VASCULAR DISEASE | ASSOCIATION | IV-THROMBOLYSIS | OCCLUSION | Acute Disease | Injections, Intravenous | Humans | Middle Aged | Male | Tissue Plasminogen Activator - administration & dosage | Tomography, X-Ray Computed | Treatment Outcome | Brain Ischemia - drug therapy | Thrombolytic Therapy - methods | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Infarction, Middle Cerebral Artery - drug therapy | Urokinase-Type Plasminogen Activator - administration & dosage | Infarction, Middle Cerebral Artery - diagnostic imaging | Brain Ischemia - diagnostic imaging | Injections, Intra-Arterial
Journal Article
Details